Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma?
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractHeat shock protein 90 promotes tumor progression and survival and has emerged as a vital therapeutic target. Previously we reported that the combinatorial treatment of 17AAG/sihsp90α significantly downregulated Hsp90α mRNA and protein levels in Glioblastoma Multiforme (GBM). Here we investigated the ability of cell penetrating peptide (Tat48-60 CPP)-mediated siRNA-induced hsp90α knockdown as a single agent and in combination with 17-allylamino-17-demethoxygeldanamycin (17-AAG) to induce tumor growth inhibition in GBM and whether it possessed therapeutic implications. GBM and non-tumorigenic cells exposed to siRNA and/or 17-AAG were subsequently assessed by qRT-PCR, immunofluorescence, FACS analysis, quantitative Akt, LDH leakage and cell viability assays. PAGE was performed for serum stability assessment. A combination of siRNA/17-AAG treatment significantly induced Hsp90α gene and protein knockdown by 95% and 98%, respectively, concomitant to 84% Akt kinase activity attenuation, induced cell cycle arrest and tumor-specific cytotoxicity by 88%. Efficient complex formation between CPP and siRNA exhibited improved serum stability of the siRNA with minimal intrinsic toxicity in vitro. The preliminary in vivo results showed that combination therapy induced hsp90α knockdown and attenuated Akt kinase activity in intracranial glioblastoma mouse models. The results imply that RNAi-mediated hsp90α knockdown increases 17-AAG treatment efficacy in GBM. In addition, the cytotoxic response observed was the consequence of downregulation of hsp90α gene expression, reduced Akt kinase activity and S-G2/M cell cycle arrest. These results are novel and highlight the ability of Tat to efficiently deliver siRNA in GBM and suggest that the dual inhibition of Hsp90 has therapeutic potentials. © 2013 The Authors.
CitationMehta, A., Shervington, A., Howl, J., Jones, S. and Shervington, L. (2013) Can RNAi‐mediated hsp90α knockdown in combination with 17‐AAG be a therapy for glioma? FEBS Open Bio, 3(2013), pp. 271-278.
JournalFEBS Open Bio
PubMed ID23905009 (pubmed)
Description© 2013 The Authors. Published by Wiley. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1016/j.fob.2013.06.002
SponsorsThis study was supported by a Grant from the Sydney Driscoll Neuroscience Foundation (SDNF) and the School of Pharmacy and Biomedical Sciences (UCLan). The work was also supported by the Estonian Government through the targeted financing SF0180027s08 and the European Regional Development Fund [project Tumor‐Tech (3.2.1001.11–0008)].
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution 4.0 International
- Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma?
- Authors: Mehta A, Shervington A, Howl J, Jones S, Shervington L
- Issue date: 2013
- Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
- Authors: Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung AL, Kieran MW, Wen PY
- Issue date: 2009 Apr
- HSP27 knockdown produces synergistic induction of apoptosis by HSP90 and kinase inhibitors in glioblastoma multiforme.
- Authors: Belkacemi L, Hebb MO
- Issue date: 2014 Sep
- Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
- Authors: Ohba S, Hirose Y, Yoshida K, Yazaki T, Kawase T
- Issue date: 2010 Jan